Healthcare Industry News: Traumatic Spinal Cord Injury
News Release - September 12, 2011
InVivo Therapeutics Promotes Lauren Mitarotondo to Vice President, Operations as InVivo Prepares for Human StudiesCAMBRIDGE, Mass.--(Healthcare Sales & Marketing Network)-- InVivo Therapeutics Holdings Corp. (OTCBB:NVIV.ob ), a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced that Lauren Mitarotondo has been promoted to the newly-created position of Vice President, Operations. Reporting to Frank Reynolds, Chief Executive Officer, Ms. Mitarotondo will be responsible for daily operations including regulatory affairs, facilities, human resources, and strategic partnerships.
Commenting on Ms. Mitarotondo’s promotion Mr. Reynolds said, “Lauren has been indispensable during our early growth. Years of coordinating our efforts in the executive suite have provided Lauren with unmatched credentials to lead InVivo’s next phase of development. Lauren has led our FDA submission, our successful public offering and the establishment of our cGMP facilities. We expect to begin a pilot study in humans for acute spinal cord injury by early 2012 and as our pipeline is advancing, we need to continue to build our leadership team. Lauren will step seamlessly into this position.”
Ms. Mitarotondo said, “I am very excited to play an even more important role at InVivo as we continue to rapidly expand. InVivo has provided me with endless potential for personal and professional growth, and I look forward to contributing to the continued success of the Company.”
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is focused on utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed as a result of Traumatic Spinal Cord Injury. The company was founded in 2005 on the basis of proprietary technology co-invented by Robert Langer, ScD. Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who is affiliated with Massachusetts General Hospital.
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to sell additional shares of common stock and warrants to purchase common stock at additional closings, the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology in connection with spinal cord injuries; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including our Form 10-K and Form 10-Qs and our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.
Source: InVivo Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.